Which adverse effect is associated with dasatinib therapy?

Which adverse effect is associated with dasatinib therapy?

• A. Hemolytic anemia
• B. Anaphylaxis
• C. Fluid retention
• D. Hypoglycemia

Answer: (C)

Dasatinib therapy is known to commonly cause fluid retention as an adverse effect. This retention can manifest as peripheral edema, and patients may experience swelling, particularly in the legs and abdomen, due to the drug's impact on fluid balance. The mechanism behind this side effect is related to dasatinib's influence on the endothelial cells and sodium retention, which can alter vascular permeability and lead to increased fluid accumulation in the body. Other adverse effects of dasatinib may include hematologic abnormalities, such as thrombocytopenia or leukopenia, but fluid retention stands out as a more prominent and easily recognizable issue among patients receiving this medication. Awareness of this side effect is critical for healthcare providers to monitor and manage effectively, ensuring patients maintain their quality of life during treatment. The other options listed, while potentially serious in general oncology practice, are not typically associated with dasatinib. For instance, hemolytic anemia is not a recognized adverse reaction of this drug. Anaphylaxis can occur with any medication but is not specific to dasatinib. Hypoglycemia is also not a standard concern with dasatinib therapy, making fluid retention the most pertinent and recognized adverse effect of the treatment.

Dasatinib therapy is known to commonly cause fluid retention as an adverse effect. This retention can manifest as peripheral edema, and patients may experience swelling, particularly in the legs and abdomen, due to the drug's impact on fluid balance. The mechanism behind this side effect is related to dasatinib's influence on the endothelial cells and sodium retention, which can alter vascular permeability and lead to increased fluid accumulation in the body.

Other adverse effects of dasatinib may include hematologic abnormalities, such as thrombocytopenia or leukopenia, but fluid retention stands out as a more prominent and easily recognizable issue among patients receiving this medication. Awareness of this side effect is critical for healthcare providers to monitor and manage effectively, ensuring patients maintain their quality of life during treatment.

The other options listed, while potentially serious in general oncology practice, are not typically associated with dasatinib. For instance, hemolytic anemia is not a recognized adverse reaction of this drug. Anaphylaxis can occur with any medication but is not specific to dasatinib. Hypoglycemia is also not a standard concern with dasatinib therapy, making fluid retention the most pertinent and recognized adverse effect of the treatment.